Many new anticancer treatments are molecular targeted agents and only benefit a subgroup of patients within a histologically defined cancer Heterogeneity of treatment effects requires development of ...

Efforts to improve reporting clinical trial results have led to the development of guidelines such as those recommended by the CONSORT group. 3,4 Transparent and comprehensive reporting of subgroup ...

The identification of subgroups of patients from randomized clinical trials that are of specific interest for guiding clinical decisions can be an attractive idea; however, since such trials are ...